AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
56 hedge funds and large institutions have $101M invested in AVEO Pharmaceuticals, Inc. in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 9 closing their positions.
736% more call options, than puts
Call options by funds: $3.14M | Put options by funds: $376K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
28% more capital invested
Capital invested by funds: $79M → $101M (+$22.2M)
3% less funds holding
Funds holding: 58 → 56 (-2)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$4.47M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.14M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
+$902K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$787K |
| 5 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$617K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.99M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.34M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$964K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$342K |
| 5 |
Baird Financial Group
Milwaukee,
Wisconsin
|
-$320K |
AVEO Hedge Fund Activity: Q2 2022 in Review
56 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q2 2022, worth a combined $101M — up 28% from $79M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of AVEO and 8 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 10 added.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $4.47M. The largest seller was Millennium Management, cutting an estimated $1.99M.
- 56 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q2 2022, down from 58 in Q1 2022.
- Funds reported $101M of AVEO Pharmaceuticals, Inc. stock for Q2 2022, up 28% quarter-over-quarter.
- 8 funds opened new AVEO Pharmaceuticals, Inc. positions in Q2 2022 and 9 closed out, a net change of -1 holder.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q2 2022 was Rubric Capital Management (New York), an estimated $4.47M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q2 2022 was Millennium Management, an estimated $1.99M sold.
Based on aggregated 13F filings for Q2 2022.